Logo image of ITOS

ITEOS THERAPEUTICS INC (ITOS) Stock Fundamental Analysis

NASDAQ:ITOS - Nasdaq - US46565G1040 - Common Stock - Currency: USD

7.41  -0.07 (-0.94%)

After market: 7.41 0 (0%)

Fundamental Rating

4

Taking everything into account, ITOS scores 4 out of 10 in our fundamental rating. ITOS was compared to 571 industry peers in the Biotechnology industry. While ITOS has a great health rating, there are worries on its profitability. ITOS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ITOS had negative earnings in the past year.
ITOS had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: ITOS reported negative net income in multiple years.
In the past 5 years ITOS reported 4 times negative operating cash flow.
ITOS Yearly Net Income VS EBIT VS OCF VS FCFITOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 200M 400M

1.2 Ratios

ITOS's Return On Assets of -16.77% is amongst the best of the industry. ITOS outperforms 80.57% of its industry peers.
With an excellent Return On Equity value of -19.19%, ITOS belongs to the best of the industry, outperforming 86.27% of the companies in the same industry.
Industry RankSector Rank
ROA -16.77%
ROE -19.19%
ROIC N/A
ROA(3y)6.73%
ROA(5y)-15.75%
ROE(3y)11.27%
ROE(5y)-29.68%
ROIC(3y)N/A
ROIC(5y)N/A
ITOS Yearly ROA, ROE, ROICITOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 -50 -100 -150

1.3 Margins

ITOS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ITOS Yearly Profit, Operating, Gross MarginsITOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800 -1K

More info and screens

8

2. Health

2.1 Basic Checks

ITOS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ITOS has been increased compared to 1 year ago.
Compared to 5 years ago, ITOS has more shares outstanding
There is no outstanding debt for ITOS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ITOS Yearly Shares OutstandingITOS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M
ITOS Yearly Total Debt VS Total AssetsITOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

ITOS has an Altman-Z score of 2.05. This is not the best score and indicates that ITOS is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.05, ITOS is in the better half of the industry, outperforming 71.12% of the companies in the same industry.
ITOS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.05
ROIC/WACCN/A
WACC9.51%
ITOS Yearly LT Debt VS Equity VS FCFITOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 14.80 indicates that ITOS has no problem at all paying its short term obligations.
ITOS has a Current ratio of 14.80. This is amongst the best in the industry. ITOS outperforms 88.77% of its industry peers.
A Quick Ratio of 14.80 indicates that ITOS has no problem at all paying its short term obligations.
ITOS has a Quick ratio of 14.80. This is amongst the best in the industry. ITOS outperforms 88.77% of its industry peers.
Industry RankSector Rank
Current Ratio 14.8
Quick Ratio 14.8
ITOS Yearly Current Assets VS Current LiabilitesITOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

More info and screens

3

3. Growth

3.1 Past

ITOS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -80.06%.
Looking at the last year, ITOS shows a very negative growth in Revenue. The Revenue has decreased by -47.37% in the last year.
EPS 1Y (TTM)-80.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
Revenue 1Y (TTM)-47.37%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ITOS will show a small growth in Earnings Per Share. The EPS will grow by 4.09% on average per year.
Based on estimates for the next years, ITOS will show a very strong growth in Revenue. The Revenue will grow by 48.14% on average per year.
EPS Next Y-8.35%
EPS Next 2Y-14.23%
EPS Next 3Y-10.88%
EPS Next 5Y4.09%
Revenue Next Year263.9%
Revenue Next 2Y-27.1%
Revenue Next 3Y5.62%
Revenue Next 5Y48.14%

3.3 Evolution

ITOS Yearly Revenue VS EstimatesITOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
ITOS Yearly EPS VS EstimatesITOS Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ITOS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ITOS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ITOS Price Earnings VS Forward Price EarningsITOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ITOS Per share dataITOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

A cheap valuation may be justified as ITOS's earnings are expected to decrease with -10.88% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.23%
EPS Next 3Y-10.88%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ITOS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ITEOS THERAPEUTICS INC

NASDAQ:ITOS (2/21/2025, 8:00:02 PM)

After market: 7.41 0 (0%)

7.41

-0.07 (-0.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)03-19 2025-03-19/amc
Inst Owners95.31%
Inst Owner Change-96.72%
Ins Owners0.92%
Ins Owner Change1.58%
Market Cap270.69M
Analysts85
Price Target25.46 (243.59%)
Short Float %3.88%
Short Ratio3.83
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)33.6%
Min EPS beat(2)-15.79%
Max EPS beat(2)82.99%
EPS beat(4)3
Avg EPS beat(4)25.76%
Min EPS beat(4)-15.79%
Max EPS beat(4)82.99%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1615.69%
Min Revenue beat(2)-100%
Max Revenue beat(2)3331.37%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.15%
PT rev (3m)-27.65%
EPS NQ rev (1m)13.73%
EPS NQ rev (3m)13.85%
EPS NY rev (1m)0%
EPS NY rev (3m)15.9%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.73
P/FCF N/A
P/OCF N/A
P/B 0.43
P/tB 0.43
EV/EBITDA N/A
EPS(TTM)-3.15
EYN/A
EPS(NY)-4.11
Fwd EYN/A
FCF(TTM)-3.29
FCFYN/A
OCF(TTM)-3.21
OCFYN/A
SpS0.96
BVpS17.29
TBVpS17.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.77%
ROE -19.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)6.73%
ROA(5y)-15.75%
ROE(3y)11.27%
ROE(5y)-29.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 255.48%
Cap/Sales 8.13%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.8
Quick Ratio 14.8
Altman-Z 2.05
F-Score2
WACC9.51%
ROIC/WACCN/A
Cap/Depr(3y)226.27%
Cap/Depr(5y)175.1%
Cap/Sales(3y)8.36%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-80.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
EPS Next Y-8.35%
EPS Next 2Y-14.23%
EPS Next 3Y-10.88%
EPS Next 5Y4.09%
Revenue 1Y (TTM)-47.37%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year263.9%
Revenue Next 2Y-27.1%
Revenue Next 3Y5.62%
Revenue Next 5Y48.14%
EBIT growth 1Y-60.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.79%
EBIT Next 3Y-8.88%
EBIT Next 5YN/A
FCF growth 1Y16.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.82%
OCF growth 3YN/A
OCF growth 5YN/A